Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Please provide your email address to receive an email when new articles are posted on . Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

For multiple sclerosis, the therapy will be sold as Kesimpta by Novartis; it is administered by patients once a month through the Sensoready autoinjector pen. The FDA on Thursday approved a new ...

The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

People with relapsing-remitting and active secondary-progressive multiple sclerosis (MS), as well as those with clinically isolated syndrome (CIS, an initial neurological episode), have a new ...

An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new research ...

Basel, August 25, 2023 – Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko ® ...